Non-replicative phage particles delivering CRISPR-Cas9 to target major blaCTX-M variants
PLOS ONE · 16.05.2024 · 19 (5) · e0303555
DOI: 10.1371/journal.pone.0303555 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 16.05.2024. Verfasst von Naiyaphat Nittayasut und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Microbiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Escherichia coli, Bacteriophages. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand.
Abstract (Originalsprache)
Cluster regularly interspaced short palindromic repeats and CRISPR associated protein 9 (CRISPR-Cas9) is a promising tool for antimicrobial re-sensitization by inactivating antimicrobial resistance (AMR) genes of bacteria. Here, we programmed CRISPR-Cas9 with common spacers to target predominant bla CTX-M variants in group 1 and group 9 and their promoter in an Escherichia coli model. The CRISPR-Cas9 was delivered by non-replicative phagemid particles from a two-step process, including insertion of spacer in CRISPR and construction of phagemid vector. Spacers targeting bla CTX-M promoters and internal sequences of bla CTX-M group 1 ( bla CTX-M-15 and -55 ) and group 9 ( bla CTX-M-14, -27, -65, and -90 ) were cloned into pCRISPR and phagemid pRC319 for spacer evaluation and phagemid particle production. Re-sensitization and plasmid clearance were mediated by the spacers targeting internal sequences of each group, resulting in 3 log 10 to 4 log 10 reduction of the ratio of resistant cells, but not by those targeting the promoters. The CRISPR-Cas9 delivered by modified ΦRC319 particles were capable of re-sensitizing E . coli K-12 carrying either bla CTX-M group 1 or group 9 in a dose-dependent manner from 0.1 to 100 multiplicity of infection (MOI). In conclusion, CRISPR-Cas9 system programmed with well-designed spacers targeting multiple variants of AMR gene along with a phage-based delivery system could eliminate the widespread bla CTX-M genes for efficacy restoration of available third-generation cephalosporins by reversal of resistance in bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Microbiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
- Biochemistry Unit, Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
- Division of Bacteriology, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Research Unit in Food Safety and Antimicrobial Resistance, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Naiyaphat Nittayasut, Pattrarat Chanchaithong
Förderung
- National Research Council of Thailand
Zitieren
APA
Nittayasut, N., Yata, T., Chirakul, S., Techakriengkrai, N., & Chanchaithong, P. (2024). Non-replicative phage particles delivering CRISPR-Cas9 to target major blaCTX-M variants. PLOS ONE, 19(5), e0303555. https://doi.org/10.1371/journal.pone.0303555
Vancouver
Nittayasut N, Yata T, Chirakul S, Techakriengkrai N, Chanchaithong P. Non-replicative phage particles delivering CRISPR-Cas9 to target major blaCTX-M variants. PLOS ONE. 2024;19(5):e0303555. doi:10.1371/journal.pone.0303555
BibTeX
@article{Nittayasut2024,
author = {Nittayasut, Naiyaphat and Yata, Teerapong and Chirakul, Sunisa and Techakriengkrai, Navapon and Chanchaithong, Pattrarat},
title = {Non-replicative phage particles delivering CRISPR-Cas9 to target major blaCTX-M variants},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {5},
pages = {e0303555},
doi = {10.1371/journal.pone.0303555}
}
EUVIMED